Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 4/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5041715 | 0.73 | MIF (0.33) | — | |
| SCHEMBL5035211 | 0.66 | — | — | |
| SCHEMBL18622509 | 0.64 | ALDH1A1 (0.50) | PREP | |
| SCHEMBL6763899 | 0.59 | PREP (0.53) | PREP | |
| SCHEMBL936407 | 0.59 | MAPT (0.53) | PREP | |
| SCHEMBL5281699 | 0.59 | POLB (0.51) | PREP | |
| SCHEMBL10827924 | 0.58 | PREP (0.42) | PREP | |
| SCHEMBL14762470 | 0.58 | ALDH1A1 (0.41) | PREP | |
| SCHEMBL7588471 | 0.58 | PREP (0.42) | PREP | |
| SCHEMBL13080680 | 0.58 | PREP (0.42) | PREP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1628974-A4 | HYDANTOIN DERIVATIVES AS INHIBITORS OF TUMOR NECROSIS FACTOR-ALPHA CONVERTING ENZYME (TACE) | BRISTOL MYERS SQUIBB CO (US) | 2008-05-07 | — | — | EP | disclosed |
| US-7132432-B2 | Hydantoin derivatives as inhibitors of tumor necrosis factor-alpha converting enzyme (TACE) | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-11-07 | — | — | US | disclosed |
| EP-1628974-A2 | HYDANTOIN DERIVATIVES AS INHIBITORS OF TUMOR NECROSIS FACTOR-ALPHA CONVERTING ENZYME (TACE) | Bristol-Myers Squibb Company (US) | 2006-03-01 | — | — | EP | disclosed |
| WO-2004108086-A2 | HYDANTOIN DERIVATIVES AS INHIBITORS OF TUMOR NECROSIS FACTOR-α CONVERTING ENZYME (TACE) | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-12-16 | — | — | WO | disclosed |
| US-20040254231-A1 | Hydantoin derivatives as inhibitors of tumor necrosis factor-alpha converting enzyme (TACE) | BRISTOL-MYERS SQUIBB COMPANY | 2004-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254231-A1 | Hydantoin derivatives as inhibitors of tumor necrosis factor-alpha converting enzyme (TACE) | ADAM17, ADAMTS1, MMP3 | PREP 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.